Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Wall Street Loves These Stocks. Should You?

Despite all of Wall Street's conflict and contention, a fortunate few companies enjoy unanimous support among professional analysts. If the market's movers and shakers all believe these companies will beat the long-term averages, well, surely they will -- right?

Not so fast! With help from the 180,000 members of Motley Fool CAPS, we'll see whether these high-flying favorites deserve analysts' unwavering support.


CAPS Rating (out of 5)

CAPS Bullish Sentiment

No. Wall Street Analysts

52-Week Price Change

Teva Pharmaceutical (Nasdaq: TEVA  )





Windstream (Nasdaq: WIN  )





Source: Motley Fool CAPS.

As you can see, there's a wide range of results, so just because Wall Street loves 'em doesn't mean you have to. Use the list as a jumping-off place for your own research.

No generic opportunity
It would seem the biggest lever of future growth Teva Pharmaceutical will lean heavily on is the vaunted patent cliff facing the pharmaceutical industry. Drugmakers Pfizer (NYSE: PFE  ) and Merck  (NYSE: MRK  ) face a particularly steep drop-off, and their losses will be the gain of Teva and other generic drug outfits.

Generics already account for more than three-quarters of all prescriptions written today, and by 2015, blockbuster drugs with annual sales of $170 billion will go off patent. If you’re looking for a stock that will ride out the boom and bust of business cycles, Teva seems particularly well-suited to the task.

CAPS member talan123 likes the fact that Teva also has branded products of its own, and though that raises an ironic twist in that it will also face the loss of patent protection on drugs like Copaxone, it also means it has a diversified business line that can weather the ups and downs of volatility.

Tell us in the comments section below or on the Teva Pharmaceuticals CAPS page if you think the dual track program gives it a leg up on its rivals, and then add the stock to your watchlist to see how it eventually plays out.

Going for the win
Rural telecom provider Windstream found itself caught in a gale of higher overhead costs outpacing gains made in sales. But with 16% fewer customer connections across its voice, digital TV, and high-speed Internet access business lines, it looks like it will continue to swim against the tide.

As mobile communications grow, the importance of its landline business diminishes, even in rural areas. Rivals Frontier Communications (Nasdaq: FTR  ) and CenturyLink witnessed the same challenges of trying to emphasize higher-margin services like broadband Internet to their traditional landline customers. Windstream still saw a 27% drop in net high-speed Internet additions in the quarter.

CAPS member S4Aero believes the telecom still has a solid business plan for growth, and he’ll await its fruition while collecting the dividend, which currently yields 8%.

Solid service and a plan for the future to move into VOIP and expand their cloud and broadband offerings. The biggest risk is in the continued erosion of landline home phone service (a big part of their cash flow), but replacement as indicated should more than offset that change.

Add Windstream to the Fool's free portfolio tracker to see whether it can connect to profits once again, and let us know in the comments section below or on the Windstream CAPS page when you think it will have the wind at its back.

Agree to disagree
Tell us whether these stocks deserve to have Wall Street marching lockstep, but then check out The Motley Fool's new free report that highlights a company breaking all the rules on its way to huge, multibagger gains. The report is free, so get a copy today!

Fool contributor Rich Duprey owns shares of Pfizer, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services have recommended buying shares of Pfizer and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1787981, ~/Articles/ArticleHandler.aspx, 10/27/2016 5:04:44 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
FTR $4.17 Up +0.08 +1.96%
Frontier Communica… CAPS Rating: ***
MRK $61.29 Up +0.42 +0.69%
Merck and Co. CAPS Rating: ****
PFE $32.48 Up +0.08 +0.25%
Pfizer CAPS Rating: ****
TEVA $43.15 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****
WIN $8.23 Up +0.06 +0.73%
Windstream CAPS Rating: **